Orvepitant

N/A

Report date: 2024/06/27 20:00:09
NME

Base Information

Drug NameOrvepitant
Drug Alias Name奥维匹坦OrvepitantumGW-823296XGW-823296823296
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepressive Disorder +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcNerre Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNerre Therapeutics Ltd
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsCoughIdiopathic Pulmonary Fibrosis
Inactive IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorDepressive Disorder +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG